Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
Benjamin Lichtbroun,Saum Ghodoussipour,Vignesh T. Packiam
DOI: https://doi.org/10.21037/tau-23-569
2024-04-20
Translational Andrology and Urology
Abstract:Benjamin Lichtbroun , Saum Ghodoussipour, Vignesh T. Packiam Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA Comment on: Prasad SM, Huang WC, Shore ND, et al . Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN- 102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol 2023;210:619-29. Keywords: Non-muscle-invasive bladder cancer (NMIBC); ablative therapy; mitomycin Submitted Nov 10, 2023. Accepted for publication Feb 19, 2024. Published online Apr 18, 2024. doi: 10.21037/tau-23-569 Non-muscle-invasive bladder cancer (NMIBC) is a heterogenous disease with widely variable treatment options and outcomes depending on risk stratification. Per American Urological Association (AUA) guidelines, intermediate risk (IR) NMIBC is characterized by either a low-grade (LG) T1 tumor, a solitary high-grade (HG) Ta 3 cm, or multifocal disease (1). Thus, IR NMIBC is by definition a heterogeneous disease state. While patients with high-risk NMIBC have meaningful risk for progression and death, the primary concern with IR NMIBC is a 15–70% chance of recurrence and need for quality-of-life impacting management, due to an associated <5% risk of progression to muscle invasive bladder cancer (1). There is a non-negligible operative risk with procedures under anesthesia in the predominantly elderly and comorbid bladder cancer population, as well as morbidity from repetitive resection and intravesical therapy (2). Therefore, recent efforts have been directed towards decreasing the morbidity associated with transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy for IR NMIBC. Aqueous mitomycin has been utilized for chemoablation of NMIBC in the DeBlaCa-13 study, where patients received an intensive course of intravesical mitomycin, and compared to TURBT and adjuvant intravesical chemotherapy, had an overall decrease in the number of TURBTs performed and comparable 12-month recurrence-free survival (RFS) (3). Furthermore, chemoablative reverse thermal gel with mitomycin has been used successfully in the treatment of LG upper tract urothelial carcinoma in an effort to avoid the morbidity associated with repeated endoscopic procedures or nephroureterectomy (4). In this timely study published by Prasad et al. , the ATLAS trial compared treatment with a chemoablative reverse thermal gel containing mitomycin called UGN-102 versus TURBT alone for patients with LG IR NMIBC (5). This was a prospective phase 3 trial of 282 patients with LG IR NMIBC diagnosed on cold cup biopsy, while leaving tumor in situ. Patients either received UGN-102 with or without TURBT or TURBT alone. Both groups were found to have similar complete response (CR) rates (65% for UGN-102 group and 64% for TURBT group) and rates of disease progression 3 months after surgery. Disease-free survival (DFS) was found to be superior in the UGN-102 arm with 72% DFS at 15 months compared to 50% in the TURBT monotherapy group. Durability of response was also superior in the UGN-102 group at 18 months (5). While this study is of significant interest, there are some notable limitations. First, the study was terminated early, prior to half of the accrual goal being reached, rendering the trial underpowered to perform hypothesis testing. As the authors acknowledge, DFS was defined differently in each group—residual LG disease at 3 months was considered a DFS event in the TURBT monotherapy group but not in the UGN-102 group. This departs from typical clinical trial design that utilizes CR. In fact, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) recently presented a consensus statement that recommends CR as the primary outcome for studies investigating ablative therapy for low and IR NMIBC (6). These organizations define recurrence as histologically proven tumor of any grade or stage within the bladder, progression to muscle invasive disease, or clinical stage/grade progression, rather than residual tumor at 3-month per the ATLAS trial (6). Next, the control TURBT arm could have allowed for adjuvant intravesical therapy, as it is expected to have high rates of recurrence with TURBT alone (1). Both a single dose of intravesical chemotherapy as well as repeated instillations have both been shown to provide an absolute risk reduction of recurrence: 27% and 13–14%, respectively (7,8). For IR patients, both of these treatment modalities should be offered to patients and may explain some of the difference in DFS as one group received intra -Abstract Truncated-
urology & nephrology,andrology